Functional expression of the capsule polymerase of Neisseria meningitidis serogroup X: A new perspective for vaccine development

Glycobiology

Volumn 24, Issue 2, 2014, Pages 150-158

  Fiebig, Timm ^a   Berti, Francesco ^b   Freiberger, Friedrich ^a   Pinto, Vittoria ^b   Claus, Heike ^c   Romano, Maria Rosaria ^b   Proietti, Daniela ^b   Brogioni, Barbara ^b   Stummeyer, Katharina ^a   Berger, Monika ^a   Vogel, Ulrich ^c   Costantino, Paolo ^b   Gerardy Schahn, Rita ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

capsule polymerases; Neisseria meningitidis serogroup X; NMR; recombinant protein production; vaccine development

Indexed keywords

CARRIER PROTEIN; CSXA PROTEIN; DNA POLYMERASE; EPITOPE; OLIGOSACCHARIDE; POLYMER; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GENE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ESCHERICHIA COLI; IMMUNOBLOTTING; IN VITRO STUDY; MOLECULAR CLONING; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINE PRODUCTION;

CAPSULE POLYMERASES; NEISSERIA MENINGITIDIS SEROGROUP X; NMR; RECOMBINANT PROTEIN PRODUCTION; VACCINE DEVELOPMENT;

ANTIGENS, BACTERIAL; BACTERIAL CAPSULES; CLONING, MOLECULAR; DNA-DIRECTED DNA POLYMERASE; DRUG DISCOVERY; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, BACTERIAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; RECOMBINANT PROTEINS;

EID: 84893179484     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwt102     Document Type: Article

References (37)

1. Andreishcheva E, Vann W. 2006. Escherichia coli BL21(DE3) chromosome contains a group II capsular gene cluster. Gene. 384:113-119
2. Berti F, Romano M, Micoli F, Pinto V, Cappelletti E, Gavini M, Proietti D, Pluschke G, MacLennan C, Costantino P. 2012. Relative stability of meningococcal serogroup A and X polysaccharides. Vaccine. 30:6409-6415
3. Blattner F, Plunkett G, Bloch C, Perna N, Burland V, Riley M, Collado-Vides J, Glasner J, Rode C, Mayhew G, et al. 1997. The complete genome sequence of Escherichia coli K-12. Science. 277:1453-1462
4. Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Manassara H, Tenebray B, Kairo K, Giorgini D, Chanteau S. 2007. Meningococcal meningitis: Unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 44:657-663
5. Bundle D, Jennings H, Kenny C. 1973. An improved procedure for the isolation of meningococcal, polysaccharide antigens, and the structural determination of the antigen from serogroup X. Carbohydr Res. 26:268-270
6. Bundle D, Jennings H, Kenny C. 1974. Studies on the group-specific polysaccharide of Neisseria meningitidis serogroup X and an improved procedure for its isolation. J Biol Chem. 249:4797-4801
7. Bundle D, Smith I, Jennings H. 1974. Determination of the structure and conformation of bacterial polysaccharides by carbon 13 nuclear magnetic resonance. Studies on the group-specific antigens of Neisseria meningitidis serogroups A and X. J Biol Chem. 249:2275-2281
8. Caini S, Beck N, Yacouba H, Maiga I, Chaibou I, Hinsa I, Adakal A, Issoufou A, Kim S, Pezzoli L. 2013. From Agadez to Zinder: Estimating coverage of the MenAfriVacGäó conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012. Vaccine. 31:1597-1603
9. DeAngelis P, White C. 2002. Identification and molecular cloning of a heparosan synthase from Pasteurella multocida type D. J Biol Chem. 277:7209-7213
10. DeAngelis P, White C. 2004. Identification of a distinct, cryptic heparosan synthase from Pasteurella multocida types A, D, and F. J Bacteriol. 186:8529-8532
11. Delrieu I, Yaro S, Tamekloé TA, Njanpop-Lafourcade BM, Tall H, Jaillard P, Ouedraogo M, Badziklou K, Sanou O, Drabo A, et al. 2011. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One. 6(5):e19513
12. Djingarey M, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Preziosi MP, Zuber P, Perea W, et al. 2012. Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. Vaccine. 30:B40-B45
13. Frasch C, Preziosi MP, LaForce F. 2012. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM). Hum Vaccin Immunotherap. 8:715-724
14. Freiberger F, Claus H, Günzel A, Oltmann-Norden I, Vionnet J, Mühlenhoff M, Vogel U, Vann W, Gerardy-Schahn R, Stummeyer K. 2007. Biochemical characterization of a Neisseria meningitidis polysialyltransferase reveals novel functional motifs in bacterial sialyltransferases. Mol Microbiol. 65:1258-1275
15. Gotschlich E, Goldschneider I, Artenstein M. 1969. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med. 129:1385-1395
16. Harrison O, Claus H, Jiang Y, Bennett J, Bratcher H, Jolley K, Corton C, Care R, Poolman J, Zollinger W, et al. 2013. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 19:566-573
17. Jódar L, Feavers I, Salisbury D, Granoff D. 2002. Development of vaccines against meningococcal disease. Lancet. 359:1499-1508
18. Kavoosi M, Creagh AL, Kilburn DG, Haynes CA. 2007. Strategy for selecting and characterizing linker peptides for CBM9-tagged fusion proteins expressed in Escherichia coli. Biotechnol Bioeng. 98:599-610
19. Kristiansen P, Diomandé F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Kandolo D, Aké F, Saga I, et al. 2013. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect. 56:354-363
20. LaForce F, Okwo-Bele JM. 2011. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine. Health Afairs (Project Hope). 30:1049-1057
21. Liu T, Gotschlich E, Jonssen E,Wysocki J. 1971. Studies on the meningococcal polysaccharides. I. Composition and chemical properties of the group A polysaccharide. The Journal of Biological Chemistry. 246:2849-2858
22. Micoli F, Adamo R, Proietti D, Gavini M, Romano MR, Maclennan CA, Costantino P, Berti F. 2013. Meningococcal X polysaccharide quantification by high-performance anion-exchange chromatography using synthetic N-Acetylglucosamine-4-phosphate as standard. Anal Biochem. 442:259-261
23. Micoli F, Romano MR, Tontini M, Cappelletti E, Gavini M, Proietti D, Rondini S, Swennen E, Santini L, Filippini S, et al. 2013. The development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci USA. 110:19077-19082
24. Min H, Cowman M. 1986. Combined alcian blue and silver staining of glycosaminoglycans in polyacrylamide gels: Application to electrophoretic analysis of molecular weight distribution. Anal Biochem. 155:275-285
25. Muindi KM, McCarthy PC,Wang T, Vionnet J, Battistel M, Jankowska E, Vann WF. 2013. Characterization of the meningococcal serogroup X capsule N-Acetylglucosamine-1-phosphotransferase. Glycobiology. [Epub ahead of print].
26. Mutonga D, Pimentel G, Muindi J, Nzioka C, Mutiso J, Klena J, Morcos M, Ogaro T, Materu S, Tetteh C, et al. 2009. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Am J Trop Med Hyg. 80:619-624
27. Roberts L. 2010. Vaccine introduction. The beginning of the end for Africás devastating meningitis outbreaks? Science. 330:1466-1467
28. Schwarzer D, Stummeyer K, Haselhorst T, Freiberger F, Rode B, Grove M, Scheper T, von Itzstein M, Mühlenhoff M, Gerardy-Schahn R. 2009. Proteolytic release of the intramolecular chaperone domain confers processivity to endosialidase F. J Biol Chem. 284:9465-9474
29. Sindhuwinata N, Munoz E, Munoz F, Palcic M, Peters H, Peters T. 2010. Binding of an acceptor substrate analog enhances the enzymatic activity of human blood group B galactosyltransferase. Glycobiology. 20:718-723
30. Sørensen H, Mortensen K. 2005. Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb Cell Fact. 4:1
31. Soya N, Shoemaker G, Palcic M, Klassen J. 2009. Comparative study of substrate and product binding to the human ABO(H) blood group glycosyltransferases. Glycobiology. 19:1224-1234
32. Stephens D, Greenwood B, Brandtzaeg P. 2007. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 369:2196-2210
33. Sugiarto G, Lau K, Qu J, Li Y, Lim S, Mu S, Ames J, Fisher A, Chen X. 2012. A sialyltransferase mutant with decreased donor hydrolysis and reduced sialidase activities for directly sialylating LewisX. ACS Chem Biol. 7:1232-1240
34. Tzeng YL, Noble C, Stephens . 2003. Genetic basis for biosynthesis of the (alpha 1-4)-linked N-Acetyl-D-glucosamine 1-phosphate capsule of Neisseria meningitidis serogroup X. Infect Immun. 71:6712-6720
35. Weisgerber C, Troy F. 1990. Biosynthesis of the polysialic acid capsule in Escherichia coli K1. The endogenous acceptor of polysialic acid is a membrane protein of 20 kDa. J Biol Chem. 265:1578-1587
36. Xie O, Bolgiano B, Gao F, Lockyer K, Swann C, Jones C, Delrieu I, Njanpop-Lafourcade BM, Tamekloe T, Pollard A, et al. 2012. Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies. Vaccine. 30:5812-5823
37. Xie O, Pollard A, Mueller J, Norheim G. 2013. Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine. Vaccine. 31:2852-2861